Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year

Table 2 Demographic and clinical features of the patient population

Feature	n (224)
DIAGNOSIS
Juvenile idiopathic arthritis	100
RF-negative polyarticular	35
Enthesitis-related arthritis	24
Oligoarticular	17
Psoriatic	12
Systemic	7
RF+ polyarticular	5
Systemic lupus erythematosus	40
Inflammatory bowel disease-associated arthritis	18
Juvenile dermatomyositis	12
Idiopathic uveitis	10
Sjogren syndrome	8
Mixed connective tissue disease	7
Henoch-Schonlein purpura	5
Sarcoidosis	4
Chronic recurrent multifocal osteomyelitis	3
Other¹	14
DEMOGRAPHICS
Female sex	161 (72%)
Age at initiation of infusion (years: mean ± SD)	11.5 ± 4.2
Age in 2015² (years: mean ± SD)	13.3 ± 4.0
THERAPY
Therapy duration (start – September 30, 2017); years: mean ± SD	2.8 ± 2.4
Use of antimetabolites³	183 (82%)
Outcome of infusions used in 2015
Continued into 2016	139⁴
Patient transferred care	19
Changed to home/local infusions or subcutaneous administration	11
Stopped due to disease control	33
Stopped due to inefficacy	21⁴
Stopped due to adverse events	6
Stopped as per parental choice	5

¹The following diagnoses had 1 patient each: Behcet Syndrome, CREST (Calcinosis, Raynaud, Esophageal dysmotility, Sclerodactyly, Telangiectasia) syndrome, cutis laxa with restrictive lung disease, eosinophilic granulomatosis with polyangiitis, hyper IgD syndrome, idiopathic pulmonary hemosiderosis, immune-mediated glomerulonephritis, idiopathic thrombocytopenic purpura, mucolipidosis type IV, orbital pseudotumor, pemphigoid, primary angiitis of the central nervous system, polymyositis, relapsing polychondritis. ²Calculated as age mid-year (June 30, 2015). ³azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil. ⁴Ten patients were counted in both rows, due to switching from one infusion to another in 2015

ISSN: 1546-0096